Clinical developments of chemotherapeutic nanomedicines: Polymers and liposomes for delivery of camptothecins and platinum (II) drugs

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 5, Issue 2, 2013, Pages 130-138

  Kieler Ferguson, Heidi M ^a   Fréchet, Jean M J ^a,b   Szoka Jr, Francis C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; LIPOSOMES; PLATINUM COMPOUNDS; POLYMERS; TARGETED DRUG DELIVERY;

CAMPTOTHECIN (CPT); CLINICAL DEVELOPMENT; CONFLICT OF INTEREST; CONFLICTS OF INTEREST; DELIVERY COMPANY; MACROMOLECULAR DRUGS; POLYMERIC DELIVERY; SMALL MOLECULES;

CONTROLLED DRUG DELIVERY;

AP 5280; AP 5346; CAMPTOTHECIN; CISPLATIN; CRLX 101; CT 2106; DICARBOXYLIC ACID; IRINOTECAN; LIPOPLATIN; LIPOSOME; LIPOXAL; MACROGOL; MAG CPT; N (2 HYDROXYPROPYL) METHACRYLAMIDE; NC 4016; NC 6004; OXALIPLATIN; PEGAMOTECAN; PLATINUM; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; POLYGLUTAMIC ACID; POLYMER; TOPOTECAN; UNCLASSIFIED DRUG; XMT 1001;

ARTICLE; CANCER CHEMOTHERAPY; DNA ADDUCT; DRUG STRUCTURE; DRUG TARGETING; LIPOSOMAL DELIVERY; MONONUCLEAR PHAGOCYTE; NANOMEDICINE; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL;

EID: 84873740425     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1209     Document Type: Article

References (74)

1. Guengerich FP. CYTOCHROME P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999, 39:1-17.
2. Courjault F, Leroy D, Coquery L, Toutain H. Platinum complex-induced dysfunction of cultured renal proximal tubule cells. A comparative study of carboplatin and transplatin with cisplatin. Arch Toxicol 1993, 67: 338-346.
3. Scott DO, Bindra DS, Sutton SC, Stella VJ. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats. Drug Metab Dispos 1994, 22: 438-442.
4. Morgan MT, Carnahan MA, Immoos CE, Ribeiro AA, Finkelstein S, Lee SJ, Grinstaff MW. Dendritic molecular capsules for hydrophobic compounds. J Am Chem Soc 2003, 125: 15485-15489.
5. Müller CE. Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Chem Biodivers 2009, 6: 2071-2083.
6. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2: 347-360.
7. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4: 145-160.
8. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2: 751-760.
9. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83: 761-769.
10. Fox ME, Szoka FC, Fréchet JMJ. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc Chem Res 2009, 42: 1141-1151.
11. Yoo J-W, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 2011, 10: 521-535.
12. Venditto VJ, Szoka FC, Jr. Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev 2012. doi:10.1016/j.addr.2012.09.038.
13. Kohane DS, Langer R. Biocompatibility and drug delivery systems. Chem Sci 2010, 1: 441-446.
14. Zhu M, Nie G, Meng H, Xia T, Nel A, Zhao Y. Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Acc Chem Res 2012 doi:10.1021/ar300031y.
15. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46: 6387-6392.
16. Gillies ER, Fréchet JMJ. Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. J Am Chem Soc 2002, 124: 14137-14146.
17. Kratz F, Mueller IA, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. ChemMedChem 2007, 3: 20-53.
18. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6: 688-701.
19. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991, 1066: 29-36.
20. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006, 1: 297-315.
21. Phillips MC, Johnson WJ, Rothblat GH. Mechanisms and consequences of cellular cholesterol exchange and transfer. Biochim Biophys Acta 1987, 906: 223-276.
22. Kan CC, Yan J, Bittman R. Rates of spontaneous exchange of synthetic radiolabeled sterols between lipid vesicles. Biochemistry 1992, 31: 1866-1874.
23. Hamilton JA. Fast flip-flop of cholesterol and fatty acids in membranes: implications for membrane transport proteins. Curr Opin Lipidol 2003, 14: 263-271.
24. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993, 1151: 201-215.
25. Barenholz Y. (Chezy) Doxil̂®-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160: 117-134.
26. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51: 691-744.
27. Hrkach J, Hoff DV, Ali MM, Andrianova E, Auer J, Campbell T, Witt DD, Figa M, Figueiredo M, Horhota A, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4: 12839.
28. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata1, 2. J Am Chem Soc 1966, 88: 3888-3890.
29. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994, 37: 40-46.
30. Venditto VJ, Simanek EE. Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm 2010, 7: 307-349.
31. Hecht JR. Gastrointestinal toxicity or irinotecan. Oncology 1998, 12: 72-78.
32. Armstrong D, O'Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist 1998, 3: 4-10.
33. Verma RP, Hansch C, About M, Article T. Camptothecins: a SAR/QSAR study. Pharm Res 2009, 109: 213-235.
34. Schoemaker NE, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, et al. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer 2002, 87: 608-614.
35. Sarapa N, Britto MR, Speed W, Jannuzzo M, Breda M, James CA, Porro M, Rocchetti M, Wanders A, Mahteme H, et al. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol 2003, 52: 424-430.
36. Bissett D, Cassidy J, de Bono JS, Muirhead F, Main M, Robson L, Fraier D, Magnè ML, Pellizzoni C, Porro MG, et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br J Cancer 2004, 91: 50-55.
37. Wachters FM, Groen HJM, Maring JG, Gietema JA, Porro M, Dumez H, de Vries EGE, van Oosterom AT. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br J Cancer 2004, 90: 2261-2267.
38. Rowinsky EK, Rizzo J, Ochoa L, Takimoto CH, Forouzesh B, Schwartz G, Hammond LA, Patnaik A, Kwiatek J, Goetz A, et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 2003, 21: 148-157.
39. Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, et al. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 2007, 13: 5855-5861.
40. Bennet N. 2011 AACR-NCI-EORTC International Conference: molecular targets and cancer therapeutics. Lancet Oncol 2012, 13: 18.
41. Yurkovetskiy AV, Fram RJ. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv Drug Deliv Rev 2009, 61: 1193-1202.
42. Gitler MS, Monks A, Sausville EA. Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic. Mol Cancer Ther 2003, 2: 929-932.
43. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58: 621-681.
44. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006, 5: 649-659.
45. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006, 5: 1854-1863.
46. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc 2007, 82: 751-770.
47. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc 2007, 82: 1271-1286.
48. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83: 584-594.
49. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61: 1203-1213.
50. CRLX101 Plus Bevacizumab in Advanced RCC. Available at: http://clinicaltrials.gov/show/NCT01625936. (Accessed August 2, 2012).
51. Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer. Available at: http://clinicaltrials.gov/show/NCT00291785. (Accessed August 2, 2012).
52. Boulikas T, Pantos A, Bellis E, Christofis P. Platinum drugs. In: Missailidis S, ed. Anticancer Therapeutics. West Sussex: John Wiley & Sons; 2008, 55-78.
53. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 2004, 11: 559-595.
54. Kostova I. Platinum complexes as anticancer agents. Recent Pat Anticancer Drug Discov 2006, 1: 1-22.
55. Wang X, Guo Z. Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents. Dalton Trans 2008, 1521-1532.
56. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem Rev 2007, 107: 1387-1407.
57. Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, de Boer RF, Pluim D, Beijnen JH, Schellens JHM, Droz J-P. A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 2004, 10: 3386-3395.
58. Nowotnik DP, Cvitkovic E. ProLindac (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv Drug Deliv Rev 2009, 61: 1214-1219.
59. Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, et al. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer 2011, 104: 593-598.
60. Matsumura Y. Polymeric micellar delivery systems in oncology. Jpn J Clin Oncol 2008, 38: 793-802.
61. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010, 39: 8113-8127.
62. Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res 2006, 26: 1489-1493.
63. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, Peters AM, Stewart JS. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001, 12: 493-496.
64. Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 2002, 49: 201-210.
65. Perez-Soler R, Lopez-Berestein G, Lautersztain J, Al-Baker S, Francis K, Macias-Kiger D, Raber MN, Khokhar AR. Phase I clinical and pharmacological study of liposome-entrapped cis-Bis-neodecanoato-trans-R, R, -1, 2-diaminocyclohexane platinum(II). Cancer Res 1990, 50: 4254-4259.
66. Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. A phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol 2006, 58: 759-64.
67. A phase II trial of ProLindacTM and Paclitaxel combination as second line-treatment in platinum pretreated patients with advanced ovarian cancer. Available at: https://www.clinicaltrialsregister.eu. (Accessed August 2, 2012).
68. NC-6004(Nanoplatin) and gemcitabine to treat pancreatic cancer in Asia. Available at: http://clinicaltrials.gov/show/NCT00910741. (Accessed August 2, 2012).
69. Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, Lampaki S, Politis N, Karanikas C, Kosmas C. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 2010, 68: 240-247.
70. Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK, Stathopoulos JG Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep 2006, 15: 1201-1204.
71. Stathopoulos GP, Antoniou D, Dimitroulis J, Michalopoulou P, Bastas A, Marosis K, Stathopoulos J, Provata A, Yiamboudakis P, Veldekis D, et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol 2010, 21: 2227-2232.
72. Farhat FS, Temraz S, Kattan J, Ibrahim K, Bitar N, Haddad N, Jalloul R, Hatoum HA, Nsouli G, Shamseddine AI. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer. Clin Breast Cancer 2011, 11: 384-389.
73. Jehn CF, Boulikas T, Kourvetaris A, Kofla G, Possinger K, Lüftner D. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 2008, 28: 3961-3964.
74. Koukourakis MI, Giatromanolaki A, Pitiakoudis M, Kouklakis G, Tsoutsou P, Abatzoglou I, Panteliadou M, Sismanidou K, Sivridis E, Boulikas T. Concurrent liposomal cisplatin (lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. Int J Radiat Oncol Biol Phys 2010, 78: 150-155.